Quick Answer
SUPERNUS PHARMACEUTICALS, INC. reported Total Revenue of $718.95 million for the year ending 2025.
- SUPERNUS PHARMACEUTICALS, INC. showed an increase of +8.6% in Total Revenue from 2024 to 2025.
- This data is from SUPERNUS PHARMACEUTICALS, INC.'s annual report (Form 10-K), filed with the SEC on March 2, 2026.
- XBRL data for this metric is available from 2011 to 2025 (17 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2012: $91.0 thousand | Q3 2012: $91.0 thousand | Q1 2013: $147.0 thousand | Q2 2013: $281.0 thousand | Q3 2013: $1.26 million | Q1 2014: $9.08 million | Q2 2014: $29.68 million | Q3 2014: $52.49 million | Q1 2015: $28.13 million | Q2 2015: $35.05 million | Q3 2015: $39.36 million | Q1 2016: $44.19 million | Q2 2016: $51.63 million | Q3 2016: $56.81 million | Q1 2017: $57.58 million | Q2 2017: $75.83 million | Q3 2017: $80.40 million | Q4 2017: $88.44 million | Q1 2018: $90.43 million | Q2 2018: $99.54 million | Q3 2018: $103.00 million | Q4 2018: $115.93 million | Q1 2019: $85.47 million | Q2 2019: $104.70 million | Q2 2019: $104.70 million | Q3 2019: $102.14 million | Q3 2019: $102.14 million | Q4 2019: $100.45 million | Q1 2020: $94.98 million | Q1 2020: $94.98 million | Q2 2020: $126.73 million | Q3 2020: $155.14 million | Q1 2021: $130.93 million | Q2 2021: $141.33 million | Q3 2021: $148.46 million | Q1 2022: $152.51 million | Q2 2022: $170.05 million | Q3 2022: $177.35 million | Q1 2023: $153.76 million | Q2 2023: $135.56 million | Q3 2023: $153.88 million | Q1 2024: $143.64 million | Q2 2024: $168.33 million | Q3 2024: $175.69 million | Q1 2025: $149.82 million | Q2 2025: $165.45 million | Q3 2025: $192.10 million.
- Over the full 17 years of available data (2011 to 2025), SUPERNUS PHARMACEUTICALS, INC.'s Total Revenue has grown by 89,433.3%.
- Historical annual values: Fiscal year 2025: $718.95 million | Fiscal year 2024: $661.82 million | Fiscal year 2023: $607.52 million | Fiscal year 2022: $667.24 million | Fiscal year 2021: $579.78 million | Fiscal year 2020: $520.40 million | Fiscal year 2019: $392.76 million | Fiscal year 2019: $392.76 million | Fiscal year 2018: $408.90 million | Fiscal year 2018: $408.90 million | Fiscal year 2017: $302.24 million | Fiscal year 2016: $215.00 million | Fiscal year 2015: $147.47 million | Fiscal year 2014: $92.68 million | Fiscal year 2013: $12.02 million | Fiscal year 2012: $1.48 million | Fiscal year 2011: $803.0 thousand.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: